SpyGlass Pharma, Inc.

SpyGlass Pharma is a late-stage biopharmaceutical company pioneering a future where sustained drug delivery simplifies chronic eye disease management, helping patients experience treatment that lasts and vision that endures.

We believe cataract surgery is an opportunity to do more for patients living with glaucoma. Our approach is built around a simple idea: Two diseases. One familiar procedure. By addressing glaucoma during cataract surgery, we aim to reduce the burden of daily drops, provide sustained IOP control, and enable more surgeons to participate in long-term glaucoma management.

Our lead product candidate, the Bimatoprost Drug Pad–IOL System (BIM-IOL System), is designed to deliver robust, durable IOP control while preserving the visual outcomes surgeons expect from modern cataract surgery.

Beyond the BIM-IOL System, we are advancing the BIM-DRS System, which extends our technology to a broader glaucoma patient population outside of cataract surgery, with the potential for lifelong disease management.